South Korea’s Celltrion Inc said on Monday it has received emergency use authorisation (EUA) from the U.S. Food & Drug Administration (FDA) for its rapid COVID-19 testing kit Sampinute, which boosted shares of the company and its affiliates. Celltrion said Sampinute delivers coronavirus test results within 10 minutes, with a sensitivity of around 94%. The authorisation came three months after requesting approval in late July and the product has already been launched in the United States in August, according to the company statement.
